AU2019431238B2 - Pharmaceutical composition containing tbn or salt or hydrate thereof and preparation method therefor - Google Patents

Pharmaceutical composition containing tbn or salt or hydrate thereof and preparation method therefor Download PDF

Info

Publication number
AU2019431238B2
AU2019431238B2 AU2019431238A AU2019431238A AU2019431238B2 AU 2019431238 B2 AU2019431238 B2 AU 2019431238B2 AU 2019431238 A AU2019431238 A AU 2019431238A AU 2019431238 A AU2019431238 A AU 2019431238A AU 2019431238 B2 AU2019431238 B2 AU 2019431238B2
Authority
AU
Australia
Prior art keywords
tbn
pharmaceutical composition
enteric
active ingredient
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019431238A
Other languages
English (en)
Other versions
AU2019431238A1 (en
Inventor
Wei Liu
Yewei Sun
Yuqiang Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Magpie Pharmaceuticals Co Ltd
Original Assignee
Guangzhou Magpie Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Magpie Pharmaceuticals Co Ltd filed Critical Guangzhou Magpie Pharmaceuticals Co Ltd
Publication of AU2019431238A1 publication Critical patent/AU2019431238A1/en
Application granted granted Critical
Publication of AU2019431238B2 publication Critical patent/AU2019431238B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019431238A 2019-02-27 2019-07-31 Pharmaceutical composition containing tbn or salt or hydrate thereof and preparation method therefor Active AU2019431238B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910143739.0 2019-02-27
CN201910143739.0A CN111617047B (zh) 2019-02-27 2019-02-27 一种含tbn或其盐或其水合物的药物组合物及其制备方法
PCT/CN2019/098709 WO2020173046A1 (zh) 2019-02-27 2019-07-31 一种含tbn或其盐或其水合物的药物组合物及其制备方法

Publications (2)

Publication Number Publication Date
AU2019431238A1 AU2019431238A1 (en) 2021-10-28
AU2019431238B2 true AU2019431238B2 (en) 2023-09-28

Family

ID=72238958

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019431238A Active AU2019431238B2 (en) 2019-02-27 2019-07-31 Pharmaceutical composition containing tbn or salt or hydrate thereof and preparation method therefor

Country Status (8)

Country Link
US (1) US20220168299A1 (https=)
EP (1) EP3932407B1 (https=)
JP (1) JP7404381B2 (https=)
CN (1) CN111617047B (https=)
AU (1) AU2019431238B2 (https=)
CA (1) CA3131558A1 (https=)
IL (1) IL285865A (https=)
WO (1) WO2020173046A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109893511B (zh) * 2017-12-11 2022-07-12 湖北舒邦药业有限公司 一种地红霉素肠溶片肠溶包衣、其制备方法以及一种地红霉素肠溶片
CN116023340A (zh) * 2019-04-01 2023-04-28 广州喜鹊医药有限公司 硝酮嗪晶型、制备方法及应用
CN112516100A (zh) * 2020-12-31 2021-03-19 珠海润都制药股份有限公司 一种艾司奥美拉唑镁肠溶片及其制备方法
CN116650411A (zh) * 2022-02-25 2023-08-29 广州喜鹊医药有限公司 一种注射用硝酮嗪药物组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101987081A (zh) * 2010-07-16 2011-03-23 钟术光 一种控释制剂
CN104922086A (zh) * 2015-06-21 2015-09-23 珠海润都制药股份有限公司 一种质子泵抑制剂肠溶片的制备方法
CN105963298A (zh) * 2016-05-06 2016-09-28 广州喜鹊医药有限公司 川芎嗪衍生物硝酮嗪在预防和治疗脑损伤疾病中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1683345A (zh) * 2005-02-28 2005-10-19 杨喜鸿 川芎嗪的协同增效药用酸盐及其制备方法
CN101269049B (zh) * 2008-04-25 2012-01-25 广东药学院 磷酸川芎嗪微孔渗透泵控释片及其制备方法
CN101468970B (zh) * 2008-04-25 2011-05-11 暨南大学 一种硝酮类化合物及其制备方法和在制药中的应用
EP3187171B1 (en) * 2012-04-30 2024-09-25 Tillotts Pharma AG A delayed release drug formulation
CN108653236B (zh) * 2017-03-31 2025-03-25 上海惠永药物研究有限公司 一种生物膜包载药物纳米晶体的制备方法及其用途
CN107417631A (zh) * 2017-08-04 2017-12-01 广州喜鹊医药有限公司 一种氘代硝酮嗪化合物及其制备方法和在制药中的应用
CN108815128B (zh) * 2018-05-25 2022-01-07 广东药科大学 一种磷酸-川芎嗪微孔渗透泵控释片的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101987081A (zh) * 2010-07-16 2011-03-23 钟术光 一种控释制剂
CN104922086A (zh) * 2015-06-21 2015-09-23 珠海润都制药股份有限公司 一种质子泵抑制剂肠溶片的制备方法
CN105963298A (zh) * 2016-05-06 2016-09-28 广州喜鹊医药有限公司 川芎嗪衍生物硝酮嗪在预防和治疗脑损伤疾病中的应用

Also Published As

Publication number Publication date
EP3932407C0 (en) 2023-10-18
CN111617047A (zh) 2020-09-04
EP3932407A4 (en) 2022-06-29
JP7404381B2 (ja) 2023-12-25
IL285865A (en) 2021-10-31
CN111617047B (zh) 2021-06-22
AU2019431238A1 (en) 2021-10-28
CA3131558A1 (en) 2020-09-03
US20220168299A1 (en) 2022-06-02
EP3932407B1 (en) 2023-10-18
WO2020173046A1 (zh) 2020-09-03
JP2022522005A (ja) 2022-04-13
EP3932407A1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
AU2019431238B2 (en) Pharmaceutical composition containing tbn or salt or hydrate thereof and preparation method therefor
US6709676B2 (en) Extended release oral dosage composition
US20110218216A1 (en) Extended release pharmaceutical composition of donepezil
US20100291225A1 (en) Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same
KR20100129776A (ko) 왁스를 포함하는 서방형 제형
JP2022522005A5 (https=)
US20170258749A1 (en) Oseltamivir Compositions
EP2374450B1 (en) Flupentixol compositions
US20180116967A1 (en) Extended release tablet of cyclobenzaprine
EP2416761B1 (de) Desfesoterodin in form eines weinsäuresalzes
US20100172984A1 (en) tablet dosage form comprising cetirizine and pseudoephedrine
CA2374039C (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
US20150352048A1 (en) Valsartan-amlodipine compound solid preparation and preparation method therefor
US20140343076A1 (en) Pharmaceutical compositions of lurasidone
US20150148388A1 (en) Chemical composition
US7741334B2 (en) Low dose therapy for treating viral infections
JP7084950B2 (ja) 非拍動性持続放出ベタヒスチン経口固形組成物
JP7271869B2 (ja) レボセチリジン含有錠剤
NZ573566A (en) Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders
AU2022426506B2 (en) A solid pharmaceutical composition
US12458592B1 (en) Extended release amphetamine tablets
US20100022576A1 (en) Stable and bioavailable formulations and a novel form of desloratadine
RU2810575C1 (ru) Фармацевтическая композиция, включающая мемантин и цитиколин, а также лекарственная форма на основе указанной фармацевтической композиции, включающей мемантин и цитиколин, способ ее получения и применение лекарственной формы на основе фармацевтической композиции, включающей мемантин и цитиколин
KR101220643B1 (ko) 사포그릴레이트 함유 경구투여 형태의 약제
ES2641308B1 (es) Comprimidos de metilfenidato de liberación retardada

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)